Top mRNA Therapeutics Companies

mRNA Therapeutics Market size was valued at USD 11.72 Billion in 2024 and is poised to grow from USD 12.48 Billion in 2025 to USD 20.65 Billion by 2033, growing at a CAGR of 6.5% during the forecast period (2026–2033).

The key vendors in the mRNA Therapeutics Market include Moderna, Inc., BioNTech SE, Pfizer Inc., CureVac SE, Sanofi, GSK plc, AstraZeneca plc, Arcturus Therapeutics Holdings Inc., Ethris GmbH, and Vertex Pharmaceuticals Incorporated. These companies focus on developing mRNA-based vaccines and therapies for infectious diseases, cancer, and rare genetic disorders.

The key driver of the mRNA Therapeutics Market is increasing demand for innovative vaccines and targeted treatments. Growing investments in biotechnology research, rising prevalence of infectious diseases and cancer, and advancements in mRNA delivery technologies are accelerating the development of personalized therapies and next-generation vaccines.

The key market trend in the mRNA Therapeutics Market is the expansion of mRNA applications beyond infectious disease vaccines into cancer immunotherapy and rare disease treatments. Manufacturers are advancing lipid nanoparticle delivery systems, personalized medicine approaches, and next-generation mRNA platforms to improve therapeutic effectiveness and broaden clinical applications.

North America accounted for the largest share of the mRNA Therapeutics Market, driven by substantial biotechnology research investments, advanced healthcare infrastructure, and strong pharmaceutical industry presence. Supportive regulatory frameworks, extensive clinical trial activity, and leading mRNA developers further strengthen the region’s market dominance.